NCT05022901Phase 3Active not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Study sponsor: Delcath Systems Inc. · DCTH

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-03-01Estimated

Enrollment · participants30Estimated

Source updated2023-12-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Metastatic Ocular Melanoma; Metastatic Uveal Melanoma

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

measure: Adverse Events; description: The number and type of adverse events will be assessed per CTCAE version 5.0.; timeFrame: From eligibility until death due to any cause, for up to 104 weeks

History coverage

Imported research includes version dates later than the current official API record (2023-12-21). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history